Search Results

You are looking at 61 - 70 of 491 items for :

  • Refine by Access: All x
Clear All
Full access

Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli

.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

). Of 1,685 patients who received PARPi, incidence of any AE, regardless of grade, was 98.5% (95% CI, 97.2–99.2%). Common AEs were: nausea (incidence rate, 68.9% and 95% CI, 58.7%–77.5%), fatigue (56.3%, 45.3%–66.8%), anemia (46.3%, 37

Full access

Olivia G. Fahey, Elizabeth N. Dow, Jennifer K. Piccolo, and Ticiana A. Leal

pharmacists were gastrointestinal (n=15) and dermatologic (n=6). Endocrine (n=7) and dermatologic (n=7) were the most common grade 1 or 2 irAEs identified by other providers. There were 4 grade 3 irAEs (endocrine, fatigue, liver, and pneumonitis) identified by

Full access

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister

The median number of treatment cycles delivered was 2 for both groups (ranges, <1–13 for Group A; <1–15 for Group B). The most common cetuximab-related adverse events (all grades) among treated subjects included rash, fatigue, and hypomagnesemia

Full access

Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov

abdominal pain. He experienced a significant unintentional 35-pound weight loss over 6 months with associated fatigue, loss of appetite, abdominal pain, and light-colored stools. Physical examination findings were notable for scleral icterus and jaundice. In

Full access

Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker

had been well until 1 month before admission, when she noted fatigue, a 25-pound weight loss with concurrent otitis media, and sinus infections lasting 4 weeks. She was evaluated by her primary care physician and found to have new-onset anemia and

Full access

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

study can be found on the Alberta Health Services website. 11 Edmonton Symptom Assessment System: The ESAS 12 is a self-report questionnaire that asks patients to rate the severity of their current suffering regarding 9 common symptoms (pain, fatigue

Full access

Kamya Sankar and Brady L. Stein

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly

Full access

Giuseppe Curigliano

in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of

Full access

Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, and Kurt R. Oettel

mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional